Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
'wasdeafonce' OK, If you say so. I guess I kinda believe you, I guess! GLTA Play it as you see it
I don't know if Insiders are buying I'm just commenting on the article.
how do you know an insider is buying his shares...?..could be anyone on open market...that is part maybe all the reason this has been stuck forever...constant drain here...you would think they would let it go up...doesn't everyone on inside win more up than flat/down
Hmmm an insider is buying Ellins shares. Maybe it was part of his exit he had to sell off his shares as part of retirement?
Craig Ellins Sells 100,000 Shares of GB Sciences Inc (OTCMKTS:GBLX) Stock
GB Sciences Inc(OTCMKTS:GBLX) insider Craig Ellins sold 100,000 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $0.26, for a total value of $26,000.00. Following the completion of the sale, the insider now directly owns 5,761,000 shares of the company’s stock, valued at $1,497,860. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
GB Sciences Inc (GBLX) traded up 1.953% during midday trading on Monday, reaching $0.261. The company had a trading volume of 287,746 shares. The company has a 50-day moving average of $0.28 and a 200-day moving average of $0.31. GB Sciences Inc has a 12-month low of $0.21 and a 12-month high of $0.65. The stock’s market capitalization is $33.32 million.
Get GB Sciences Inc alerts:
About GB Sciences
GB Sciences, Inc, formerly Growblox Sciences, Inc, is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments.
https://rinconhillneighbors.org/2017/08/07/craig-ellins-sells-100000-shares-of-gb-sciences-inc-otcmktsgblx-stock.html
Company appears to be done for. 8k shows big disposal of shares by former director. Bear trend imminent
'Shaaaaaaarrk' I have never been deaf, dumb, blind, one legged or trading impaired. Can't speak for those that are ;)
'wasdeafonce' Was that being deaf & dumb? If you sell, you lose all the potential that GBLX has grown into & become! GLTA Play it as you see it
GB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market
LAS VEGAS, Aug. 2, 2017/PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is proud to announce an agreement with the Los Coyotes Band of Cahuilla and Cupeno Indians (Los Coyotes) for the purposes of establishing cannabis operations on the tribe's lands located near Warner Springs, California.
The nonbinding Joint Statement of Intent outlines plans to build and operate facilities to grow, manufacture, and distribute commercial cannabis and cannabis products in the State of California.
This is the first time a publicly traded US cannabis cultivation company and a federally recognized Native American tribe have announced a commercial cannabis venture in California.
GB Sciences will construct facilities on designated areas of tribal land for the business of cultivation, manufacturing and other commercial cannabis activities. Los Coyotes will receive 40 percent of the venture's net profits, of which 10 percent will fund tribal childhood education and elder assistance programs.
GB Sciences John Poss said, "The tribe and its leadership are ideal partners for GB Sciences. We share the same attitudes toward the business, the same intentions for the quality of the product, and the same positive goals for tribe. It is difficult to imagine a better way to enter the gigantic Californiacannabis market."
Los Coyotes Tribal Chairman Shane Chapparosa said, "We welcome this important partnership with GB Sciences. They are the ideal partners to facilitate Los Coyotes' move into California's cannabis market. In addition to producing much-needed revenue and jobs for the tribe, and the partnership will confer a distinct benefit to patients as we work with GB to develop strains with great therapeutic value."
The Statement is subject to definitive agreements between the parties to be completed and executed in the near future. Once consummated, the agreement between the Tribe and GB will result in a new entity, which would be initially funded by advances from GB, and which ultimately would be owned 60 percent by GB Sciences and 40 percent by the tribe, with GB being the manager of the operation.
The Statement also makes it clear that all applicable rules and regulations will be respected by both parties, and that appropriate, applicable licensure pursuant to, or replicating, the Medicinal and Adult Use Cannabis Regulation and Safety Act will be sought. Further, the Statement is clear that no steps will be taken that could possibly compromise or abrogate the Tribe's sovereign status.
http://www.prnewswire.com/news-releases/gb-sciences-joins-with-los-coyotes-band-of-cahuilla-and-cupeno-indians-as-it-enters-the-gigantic-california-cannabis-market-300498673.html
So everyone has bailed on this little beauty?
News from California.
Good news today for medical marijuana sector
https://merryjane.com/news/department-of-justice-indicates-no-changes-to-federal-marijuana-enforcement-yet
Well in the meantime enjoy the cheapies. When it pays off big time you'll be happy about the outcome
I guess this is like a 6 month to 1 year+ hold. That is quite long. I'm a day trader so yeah......:(
Patience pays.. it's coming my friend. Bank on it
I just want results. Getting impatient to be honest. Stock price to the moon :)
The ONLY approved grower for our entire state for medical marijuana. Cha-ching
In at .28, praying it goes back up after sessions drama
'noahrobertjackson' 2 points{pov}, first & foremost, this is an EMERGING industry, which means that a clear path to success has not been widely established in the past, therefore, the trials & tribulations of a new industry are the same that every other new emerging industry has faced in the past. This is not going to be without its bumps on the road, specially, since @ one time, MJ was considered illegal & carried profound legal penalties.
Secondly, the overall MJ market is down, that's because the political climate in DC, when it comes to MJ, is @ this point & time a murky puddle with mixed messages, this may take another year or two before clarity about what is acceptable under Federal law & what is not becomes crystallized. Patience will reward those with insight & fortitude of will. GLTY Play it as you see it.
Big days ahead here. Rally on Sessions,resigination.
Shark. What is really going on and what is BS.
U r borderline genius. So is my brother in law and
Others I know. So just give me your insight. Don't tell me you don't know.
Tell me your gut. This company is in a place to prosper but can it make it.
Worldwide Clinical Trials is developing a pre-IND plan and designing pilot studies for evaluating the effectiveness of GB Sciences’ proprietary cannabis-based therapeutic, says CMSO.
As part of the consulting services agreement, Worldwide Clinical Trials will evaluate the cannabis company’s intellectual property portfolio and will assist with pre-IND planning.
Worldwide’s chief medical and scientific officer, Michael F. Murphy, MD, Ph.D., told us the companies held a meeting earlier this year to formulate a strategy for approaching clinical development considering the available nonclinical data, GB Sciences’ pipeline status, the competitive environment, and the potential unmet clinical need.
GB Sciences' wholly owned subsidiary, Growblox Life Sciences, has filed three provisional patent applications to protect complex mixtures derived from the cannabis plant, which the company said address twenty-six different disease-specific formulations within its intellectual property portfolio.
Following the meeting, three disease-specific formulations were selected for further development. Moving forward, the Morrisville, NC-based contract research organization (CRO) will focus on developing two formulations for pilot human studies in Nevada. It will also develop the third formulation for preclinical studies prior to an IND filing for an official FDA-registered clinical trial.
“Worldwide has never conducted a cannabis study,” Murphy said, noting that the field is relatively immature regarding good clinical practice (GCP) investigations in cannabis.
The company has, however, conducted GCP studies in all the clinical targets in which GB sciences has expressed interest and has provided consulting services for cannabis programs for two other companies in addition to GB Sciences. “We estimate there are approximately 30 companies active in the space,” Murphy added.
“These companies [in this space] have different approaches that either exploit unique devices (or other methods of delivery), or, they examine different active entities within the cannabis plant – the range of clinical targets is impressive and would span all of the therapeutic areas in which Worldwide has competency,” he explained.
According to Murphy, the opportunities and challenges associated with the GB portfolio will share many commonalities with other pharmaceutical companies. These similarities will provide some “predictability to the milestones and timelines likely to be encountered during clinical research, and enables Worldwide to participate in advancing solutions in advance of program initiation,” he added.
GB Sciences has established discovery and manufacturing capabilities within their organization, and as such, Murphy explained Worldwide will assist in providing access to clinical trial methods and operations as a part of the team required for clinical development.
“We will specifically help to inform the pre-IND plan for the development of cardiovascular therapies and to design pilot studies for evaluating the effectiveness of both Parkinson’s disease and chronic pain formulations,” he added.
Next steps for the CRO include introducing the therapeutic opportunities at GB Sciences to others within the organization and to acquaint its operational and regulatory staff with the GB Science rationale and potential clinical utility of the products under development– and, as Murphy said, to “help GB Sciences move toward clinical evaluation as expeditiously and efficiently as possible.”
http://mobile.outsourcing-pharma.com/Clinical-Development/Worldwide-Clinical-Trials-advancing-cannabis-based-formulations
Are referring to the growblox growing units?
Your not saying gb sciences under Mr Poss is a hoax?
"GrowBlox was just a hoax"
PPS is under attack by former CEO Ellins. He has been dumping personal shares for retirement money. GrowBlox was just a hoax for selling shares.
I see that outstanding shares has increased from 110M a few weeks ago to 127.7M. Anyone know the reason for this
Good point, I didn't think of that fact.
GB Sciences has decided to focus its drug development forces on three cannabinoid therapies in its pipeline, and it has tapped Worldwide Clinical Trials to assess its intellectual property portfolio and to help with pre-IND planning.
Through its subsidiary Growblox Life Sciences formed last July, the company isplanning pilot human studies in Nevada for two formulations for Parkinson’s disease and chronic pain, respectively, with future IND-enabled clinical trials in other states; while another cardiovascular candidate will be directly put to FDA-registered IND after preclinical studies.
Sales of whole marijuana for nonmedical use have been legalized in Nevada since July 1 after state legislators passed a bill last November, while access to medicinal cannabis allowed among people with certain conditions within the state dates back to 2001.
Instead of whole plants, the drug candidates that the life sciences arm of GB Sciences develops are actually extractions. The company touts that its chronic pain and Parkinson’s formulations do not contain delta-9 tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana, and thus are less likely to be abused.
Previously known as Growblox Sciences until a name change last December, GB filed its first patent applications to the U.S. Patent and Trademark Office last October. The application covers cannabis-derived mixtures of formulations for neuroprotection, intended for treating neurodegenerative diseases like Parkinson’s, Alzheimer’s and Huntington’s. The company later filed two more patent applications: one in February, covering cannabinoid therapies for inflammatory disorders, and another one in May for myrcene-containing mixtures for chronic pain and heart diseases.
After scientific validation and market analysis, the cannabis specialist has decided to first pursue the development of three selected formulations out of all 26 it has. Worldwide will provide pre-IND consulting services, led by Michael Murphy, M.D. Ph.D., the CRO’s chief medical and scientific officer, who was instrumental in selecting the top formulations from GB Sciences’ growing portfolio.
That doesn’t mean GB Sciences intends to manage the studies on its own. Worldwide is bidding on the pilot trials and some of the preclinical work on cardiovascular indications, GB Sciences’ CSO Andrea Small-Howard, Ph.D., told FierceBiotech. She said that GB is also taking bids from other CROs over the next few months to try to find the perfect matches in different therapeutic areas, but added that Worldwide will likely be among the finalists given their close relationship.
“Worldwide has been instrumental in establishing our clinical trial designs across multiple disease categories,” said Small-Howard. “They have breadth of clinical expertise in their team that is unparalleled among CROs working with small companies.”
http://www.fiercebiotech.com/cro/gb-sciences-to-test-cannabis-based-therapies-human-taps-worldwide-clinical-trials
I know for a fact that this company holds the only cards in the medical marijuana business in Louisiana. Only provider in the whole state means big money.
does anyone like this company...or know about it..?
Many imo. Read it. Depends what's on it ??
What impact will 10k have on stock? Any suggestions?
I'm assuming we are the early birds who caught this news.??????
More news for a Monday morning.
GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational ProductsFont size: A | A | A
6:30 AM ET 7/10/17 | Comtex Newswires
GB Sciences, Inc. (OTCQB: GBLX) has added its own medical-grade retail brand to its already strong portfolio, which includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.
https://mma.prnewswire.com/media/512132/GB_Sciences_Logo.jpg
The decision to sell to the recreational market through the addition of GB Sciences' own trusted-ingredient retail brands, strengthens the Company's vertically-integrated strategy of controlling product quality and purity from seed-to-sale. Premium flower and medical-grade oils for use in vape pens and tinctures will be sold under the Cultivation Labs banner.
On July 1st, Nevada joined Colorado, Oregon, Washington, and Alaska, to become the fifth state to legalize the use of recreational cannabis. Expectations ran high for the state given its international entertainment destination, Las Vegas. This city hosts forty-two million visitors annually - many of whom will take advantage of the new law. Dispensaries reported long lines with forty-five minute waits and extended hours. One such dispensary, ReLeaf, reported 1000 customers per day vs. a previous count of only 100-150 customers per day. The Nevada Dispensary Association reported three million in sales revenue for this four-day holiday weekend.
John Poss, CEO, GB Sciences, remarked: "The arrival of recreational sales in Nevada presents a unique and well-timed opportunity for GB Sciences. It will allow the Company to self-fund the research and development of our medical formulations, while building a globally trusted brand for recreational users. What better city than Las Vegas to show the world that the quality and purity of medical grade ingredients can and should be demanded in recreational products. We look forward to satisfying this demand for every visitor that comes to town."
POTNETWORK HLDGS INC COM NEW POTN: OTC Pink - Current Information
Services : Business Services
Snapshot
Charts
News
Options
Analyst Research
Fundamentals
Earnings
Insider Activity
Last Price Today’s Change Bid (Size) Ask (Size) Day’s Range Volume Trade
0.062 -0.007 (-10.14%) -- -- -- -- 0.055 - 0.072 5,565,797
OTC Pink - Current Information Real Time Quote Last Trade as of 3:59 PM ET 7/7/17 Extended Hours Quote and Chart: Show|Hide
Open 0.06855
Previous Close 0.069
52 - Week Range 0.002 - 0.0995
12/23/16 - 6/8/17
Avg Volume (10 days)2,268,132
P/E (Trailing 12 mo.)
--
EPS (Trailing 12 mo.)
0.000
Next Earnings Date--
Market Cap 4.9 M
Shares Outstanding 70.5 M
Beta
0.6
Dividend Yield --
Dividend
--
Ex-Dividend Date --
Dividend Payable Date --
Alert me when
POTN reaches:
You bring up some good points about summer. I think once everything is rolling GBLX should hold it's own. How many shares of PO*N are there.It's not listed. Also I'm in PN*V. * = T.
I couldn't agree more, but all my sights seem to be slow. Vacations
are in full swing, part of the dog days of summer. I know there is
significant debt to overcome, but with this first harvest info and
everything going positively, I can't see why this stock is so low either.
Been watching POTN and they've turned the corner and making over $1m/month and should make $12-15m for the year after only making $1.8m last year
with no debt and still trading around .07-.08. Makes no sense.
Sounds like a plan. Good luck to us
Couldn't tell you, very strange. You know how theses things go, quite and then the pop. This seems like one of the better positioned mj companies. I'm long and adding here on dips.
It'S like a ghost town around here. I've only been around since the PR
about LSU and bought a few thousand shares. Then I read yesterday that they harvested 133 pounds of weed of which 63# sold as premium flower.
Please correct me if I'm wrong but GBLX has there own cultivation building and they also have a license to process and They have a dispensary partner. They also have apply for pharmaceutical patents.
Only 110M shares compared to another similar stock I own has over 500m
shares.
Please someone explain to me why the stock is under .30. TIA.
Good news up this morning.
GB Sciences Sells First Cannabis Harvest and Officially Enters Revenue ModeFont size: A | A | A
6:30 AM ET 7/5/17 | Dow Jones
The first cannabis crop harvest yielded 133 pounds of product from 45 lights. 63 pounds were sold as premium flower, with 66.5 pounds held back for conversion to medical grade cannabis oil.
LAS VEGAS, July 5, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has harvested its first crop and sold 63 pounds of premium flower while holding back 66.5 pounds for conversion to medical grade oil. Based on conservative estimates and production volumes, the company projects revenue of $2.8M through December 31, 2017, and will complete its full fiscal year projections (March 31, 2018) within the next few months.
GB Sciences has spent the past year-and-a-half building what has been called by many industry professionals 'the cleanest grow facility in the business'. The Las Vegas Nevada facility, built to exacting standards, grows premium cannabis flower. The flower is then used to extract medical grade oils for scientific research and medical use, creating a fully vertical operation.
The company has begun expansion of the facility, and expects to increase production and sales beginning January 2018.
"Within the next six months, we expect to complete the Phase II expansion of the facility from 200 lights to over 600 lights," said Kevin Kuethe, VP Operations for GB Sciences. "This will allow us to harvest approximately once a week and nearly triple the current production output."
"It feels really good to get these kinds of results," Kuethe continued. "We were able to achieve yields of over two pounds per light and our test results are 20% THC or better over our first two harvests. The keys to getting such high and consistent results are our state-of-the-art precision controlled growing environment, our own custom-blended nutrients, and most of all, our highly synergistic team of scientists, botanists and growers. The pride shows in what we do and how we do it."
Followers
|
209
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8109
|
Created
|
12/10/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |